- Conditions
- Musculoskeletal Pain
- Interventions
- Methylprednisolone 4Mg Tab, Acetaminophen 500Mg Tab, Ibuprofen 200Mg Oral Tablet
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Buffalo, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–135
of 135
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Intraocular Pressure, Corneal Opacity
- Interventions
- Loteprednol Etabonate 0.5% Oph Gel, Prednisolone Acetate 1% Oph Susp
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Murray, Utah
- Conditions
- IgA Nephropathy (IgAN)
- Interventions
- Avacopan, Prednisone, Methylprednisolone (drug), Prednisolone
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects
- Interventions
- Ruxolitinib, Methylprednisolone
- Drug
- Lead sponsor
- John Levine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 14
- States / cities
- Duarte, California • Tampa, Florida • Atlanta, Georgia + 10 more
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Cyclophosphamide, BCNU, Etoposide, Filgrastim, Antithymocyte globulin, Cyclosporine, Mycophenolate mofetil, Rituximab, Autologous hematopoietic stem cell transplantation (auto-HSCT), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Total lymphoid irradiation, CD34+ Cells, Solu-Medrol
- Drug · Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Post-Concussion Syndrome, Headache
- Interventions
- Methylprednisolone
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Manhasset, New York
- Conditions
- Cataract
- Interventions
- Dexamethasone, Prednisolone Acetate Ophthalmic
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- Up to 3 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 9
- States / cities
- Huntington Beach, California • Palo Alto, California • Boston, Massachusetts + 6 more
- Conditions
- Graft-Versus-Host Disease(GVHD)
- Interventions
- 5-Azacytidine
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Fanconi Anemia
- Interventions
- Bone Marrow Aspiration, Filgrastim, Genetically Engineered Hematopoietic Stem Progenitor Cells, Laboratory Biomarker Analysis, Leukapheresis, Methylprednisolone, Plerixafor, Prednisone
- Procedure · Biological · Other + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cataracts, Inflammation
- Interventions
- Difluprednate ophthalmic emulsion, 0.05%, Prednisolone acetate ophthalmic suspension, 1.0%
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- Up to 3 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Interventions
- Standard of care treatment, eculizumab
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- End Stage Renal Disease, Renal Transplant
- Interventions
- Anti-Thymocyte Globulin, TOL101, Steroids, Tacrolimus, Mycophenolate mofetil (MMF)
- Drug
- Lead sponsor
- Tolera Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 12
- States / cities
- Aurora, Colorado • Lexington, Kentucky • Ann Arbor, Michigan + 9 more
- Conditions
- Sudden Sensorineural Hearing Loss
- Interventions
- Statin, methylprednisolone, dexamethasone, Placebo
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Acute-graft-versus-host Disease
- Interventions
- Ruxolitinib 10 MG Oral Tablet, hCG, Corticosteroids
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Pemphigus
- Interventions
- Ofatumumab, Acetaminophen/paracetamol, Antihistamine (cetirizine or equivalent), Prednisone/Prednisolone
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- Not listed
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Ann Arbor, Michigan